The Italian pharmaceutical company leverages clinical-grade innovations—including its Dinaven microcirculation line with micronized Diosmin and its proprietary Arnica Arricchita™ project—as it prepares for U.S. retail and distribution expansion.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.